AOD-9604 Side Effects: Safety and Tolerability in Clinical Studies

How safe is AOD-9604?

AOD-9604 side effects data comes from six randomized, double-blind, placebo-controlled trials encompassing approximately 900 participants across the METAOD program. The key finding: the safety and tolerability profile was indistinguishable from placebo at all doses studied ^[10].

Specifically:

• No serious adverse events attributed to AOD-9604.
• No treatment-related withdrawals from any trial.
• No IGF-1 elevation at any dose level.
• No glucose intolerance or insulin resistance induced.
• No anti-AOD-9604 antibodies detected in any participant across all trials.
• Most common adverse event — mild-to-moderate headache — occurred at statistically similar rates in treatment and placebo arms ^[10].

This is the AOD-9604 side effects record from the controlled clinical literature. No post-marketing surveillance data exists because the compound was never approved as a pharmaceutical drug.

Is AOD-9604 safe?

Phase I and Phase IIb trial data, compiled and reviewed by Stier, Vos, and Kenley (2013) across all six METAOD trials, demonstrated a tolerability profile indistinguishable from placebo at doses up to 1 mg/day over 24 weeks ^[10]. No IGF-1 elevation was detected. No changes in insulin sensitivity, glucose metabolism, or carbohydrate tolerance were observed. No immunogenicity — no anti-AOD-9604 antibodies — was detected in any of approximately 900 participants.

Comprehensive preclinical toxicology independently confirmed the safety profile. Six-month chronic toxicology in rats and nine-month chronic toxicology in cynomolgus monkeys found no organ toxicity. Genotoxicology panels across multiple standard assays found no genotoxic or mutagenic signals. These data supported the GRAS designation and the nutraceutical classification ^[11].

The safety record is the most thoroughly documented aspect of the AOD-9604 literature. It is a compound with well-characterized safety and a poorly-translated efficacy signal in humans at the doses studied.

AOD-9604 and IGF-1: why this distinction matters

The absence of IGF-1 stimulation is a structural property of AOD-9604, not an incidental safety finding. The compound was specifically designed to omit the IGF-1-stimulating N-terminal domain of hGH. Full-length hGH at pharmacological doses raises IGF-1 substantially; chronic IGF-1 elevation is associated with fluid retention, carpal tunnel syndrome, insulin resistance, and theoretical concerns about tumor promotion. AOD-9604 — because it does not bind the hGH receptor and does not activate the IGF-1 axis — does not carry these hGH-associated concerns.

Across all six trials and approximately 900 participants, no IGF-1 elevation was measured in any participant at any dose ^[10]. This was not a marginal finding — it was a designed property confirmed experimentally in every trial in the program.

Regulatory and WADA context

The clean safety record supports the FDA GRAS designation for AOD-9604 as a nutraceutical ingredient ^[11]. GRAS indicates that the compound is generally recognized as safe for its intended use in foods, beverages, and dietary supplements by qualified experts — a lower threshold than drug approval, and independent of the failed pharmaceutical obesity program.

WADA prohibits AOD-9604 under S0 (Non-Approved Substances) at all times in competitive sport — not because of a documented doping mechanism, but because it is a discontinued drug candidate without current pharmaceutical approval in any jurisdiction. The S0 category captures any pharmacological substance of this regulatory status regardless of its actual performance-enhancing potential.

For the regulatory history and pharmaceutical discontinuation context, see clinical trial history. For the AOD-9604 dosage protocols studied in trials, see the dosage page. For the full frequently asked questions index, including the FDA approval question, see the FAQ page.